SolasCure has initiated a new Phase II clinical trial, CLEANVLU2, to further the development of its investigational product, ...

UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology company ...

We all encounter gels in daily life – from the soft, sticky substances you put in your hair, to the jelly-like components in various foodstuffs. While human skin shares gel-like characteristics, it ...

While human skin shares gel-like characteristics, it has unique qualities that are very hard to replicate. It combines high stiffness with flexibility, and it has remarkable self-healing ...

The company manufactures a gel called NanoSALV to help heal skin injuries, burns, infections and inflammation. “We grabbed really complex technology, in an easy-to-use-solution that can go with ...